Clinical Trial Update: Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 study evaluating B-domain deleted recombinant factor VIII (BDDrFVIII), marketed as ReFacto AF. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refacto AF (Factor VIII, recombinant)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2009-07-20